Literature DB >> 6104581

Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.

B N Swanson, D W Zaharevitz, M B Sporn.   

Abstract

The concentration of N-(4-hydroxyphenyl)-all-trans-retinamide (HPR) was determined in plasma and a variety of tissues from rats after an intravenous dose (5 mg/kg). The plasma concentration-time curve could be accurately described by a triexponential equation. The apparent volume of distribution of HPR was approximately 10-12 liter/kg and the terminal half-life was 12 hr. Metabolites of HPR were more abundant than intact drug in most tissues 24 hr after the iv dose. A 5-day excretion study with radiolabeled HPR revealed that less than 2% of a single iv dose (5 mg/kg) is excreted as unmetabolized HPR in urine and feces and that most of the radioactivity is eliminated in the feces. HPR was incompletely absorbed after an oral dose (10 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104581

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis.

Authors:  Frederic Preitner; Nimesh Mody; Timothy E Graham; Odile D Peroni; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-10-13       Impact factor: 4.310

2.  Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.

Authors:  Amit Kokate; Xiaoling Li; Bhaskara Jasti
Journal:  Invest New Drugs       Date:  2006-12-05       Impact factor: 3.651

3.  Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.

Authors:  N A Illingworth; A V Boddy; A K Daly; G J Veal
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.